The pharmaceutical industry is seeing a shift toward personalized medicines, and it’s evolving to deliver this via some exciting new tools.

A prime example is the recent announcement of ATMPS’ Hataali blockchain platform being successfully tested with the University Hospitals Birmingham NHS Foundation Trust’s system interface; denoting it as the world’s first blockchain solution for Advanced Therapeutic Medicinal Products (ATMP).

Taking the digital shift in a different direction, within the life sciences industry TraceLink has now managed to leverage cloud technologies to create the world’s largest network of pharmaceutical supply chain partners and allow them to connect seamlessly.

Add the fact that scientists from Rice University Bioengineering have used deep-learning methods to develop their Metabolite Translator, a computer system that can predict what the in-vivo metabolites of a drug could be in order to identify its potential toxicity, and it’s clear to see that times are changing!

In an industry that is notoriously non-digital, these bold developments are inevitably the foundation blocks of a new and exciting chapter in our history.

Follow us on LinkedIn to stay abreast of all the latest news and events.

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.